William Richard White
CIK 1778739 · Chief Financial Officer · last filed 2026-06-23
William Richard White is a Chief Financial Officer who has filed 73 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for IRON, was dated Jun 23, 2026. Across all open-market trades the lifetime net is −$19.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $130.5K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$130.5K
3
73
-$19.12M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IRON | Director | 1,756 | $74.30 | $130.5K | -$2.96M | 14 | 2026-06-23 |
| Ventyx Biosciences, Inc. (VTYX) Delisted | Director | 7,027 | $13.99 | $98.3K | -$1.17M | 8 | 2026-03-04 |
| Akero Therapeutics, Inc. (AKRO) Delisted | Chief Financial Officer | 0 | $54.65 | $0 | -$14.99M | 41 | 2025-12-09 |
Recent Filings
73 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-23 | IRON | Grant (A) | — | $0 | EDGAR |
| 2026-03-04 | Ventyx Biosciences, Inc. (VTYX) Delisted | Disp (D) | — | $0 | EDGAR |
| 2025-12-09 | Akero Therapeutics, Inc. (AKRO) Delisted | Disp (D) | −57,752 | $0 | EDGAR |
| 2025-09-12 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −659 | -$28.4K | EDGAR |
| 2025-07-02 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | +890 | $21.2K | EDGAR |
| 2025-06-20 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −1,634 | -$89.6K | EDGAR |
| 2025-06-13 | IRON | Grant (A) | — | $0 | EDGAR |
| 2025-06-12 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −2,804 | -$151.4K | EDGAR |
| 2025-06-06 | Ventyx Biosciences, Inc. (VTYX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-03-14 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −676 | -$30.3K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.